Navigation Links
CSL Behring Parent Company, CSL Limited, Issues Fourth Corporate Responsibility Report
Date:12/3/2012

KING OF PRUSSIA, Pa., Dec. 3, 2012 /PRNewswire/ -- CSL Behring's parent company, CSL Limited (ASX: CSL), reaffirms the company's commitment to responsible business practice and sustainable development in its fourth Corporate Responsibility Report – Our Corporate Responsibility 2012. The report details CSL's performance across key corporate responsibility priority areas for the period July 1, 2011 through June 30, 2012.

(Logo: http://photos.prnewswire.com/prnh/20100914/PH63692LOGO

The priority areas include the Company's research into new and improved medicines, ensuring the safety and quality of its broad portfolio of therapies, providing a positive and healthy work environment for employees, behaving responsibly in the global marketplace, providing charitable support for communities in need around the world and minimizing the environmental impacts of its operations. Highlights of CSL's performance in these areas include:

  • Recognition of sustainable development and leadership by the FTSE4Good Index Series in 2011 and 2012 (FTSE4Good Index objectively measures the performance of companies that meet globally recognized corporate responsibility standards);
  • Research and Development investment of A$355 million dollars, with more than 30 clinical studies in operation across our portfolio of specialty and hemophilia products, breakthrough medicines and immunoglobulin-based products;
  • Economic contribution direct to local economies of more than A$4.2 billion, including global community (stakeholders and local communities) investment of A$35.4 million;
  • 2% growth in the total workforce with year-on-year reductions in recorded rates of lost time injury frequency and medical treatment injury frequency, including an 8% and 26% reduction from 2011, respectively;
  • 4% reduction in energy and water consumption and greenhouse gas emissions per unit of plasma production.

"CSL's reputation as one of the most innovative biopharmaceutical companies in the world and our continued growth are underscored by our commitment to conducting our business responsibly, and actively contributing to the well-being of our communities," said Dr. Brian McNamee, CEO and Managing Director of CSL Limited. "Our Corporate Responsibility Report for 2012 demonstrates this ongoing commitment."

About CSL Limited
Headquartered in Melbourne, Australia, CSL Limited (AUX: CSL) is a global biopharmaceutical company that develops, manufactures and markets biotherapies to prevent and treat rare and serious human diseases. CSL owns major facilities in Australia, Germany, Switzerland and the US, and employs over 11,000 people in more than 25 countries. For more information visit www.csl.com.au.

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn. For more information visit http://www.cslbehring.com/. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma.

View Our Corporate Responsibility 2012 at http://corporateresponsibility.csl.com.au/.

Contact:
Chris Florentz 
Manager, Corporate Communications
CSL Behring                                       
King of Prussia, PA                                                                            
+1 610 878 4316 

                           


'/>"/>
SOURCE CSL Behring
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
2. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
3. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
4. Parent Project Muscular Dystrophy Endorses Senate Version of Prescription Drug User Fee Act After Patient Voice Strengthened
5. New Legislation To Make USPSTF More Transparent: Prostate Cancer Roundtable Supports Reform
6. Parents Less Likely To Develop Colds, Carnegie Mellon Research Shows
7. National Call-to-Action to Boost Meningitis Vaccination Rates Supported by Leading Health Organizations, Urges St. Louis Parents to Vaccinate Preteens and Teens
8. National Call-to-Action to Boost Meningitis Vaccination Rates Supported by Leading Health Organizations, Urges Nashville Parents to Vaccinate Preteens and Teens
9. National Call-to-Action to Boost Meningitis Vaccination Rates Supported by Leading Health Organizations, Urges Minneapolis-St. Paul Parents to Vaccinate Preteens and Teens
10. TUV Rheinland Confirms Apparent Fraud in Mislabeling of DRX Products Manufactured by HTRD and Excite Medical
11. Webcams Help Parents Keep Watch Over Their Babies During Hurricane Isaac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... April 18, 2017 Research and Markets has ... report to their offering. ... The global arthroscopy devices market to grow at a CAGR of ... Arthroscopy Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:4/18/2017)... BLOOMINGTON, Minn. , April 18, ... IMMY ) ("Imprimis"), an ophthalmology-focused pharmaceutical company, and ... today announced the signing of a three-year exclusive ... will deploy a dedicated sales team to introduce ... U.S., primarily focused in 13 states in the ...
(Date:4/18/2017)... , April 18, 2017 Research ... of the United States Molecular Imaging Equipment and Radiopharmaceuticals Market, ... ... in molecular imaging equipment revenues as well as growth in ... This will provide value to market participants that design and ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... RawTrition now brings you BioEnergy which is a ... SUPERFOODS! , RawTrition is taking nutrients to the next level! The ... recognizes its raw form (unlike the synthetically made options that are on the market). ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... ecosystem and domain expertise for sponsors and CROs to speed clinical development, ... management (RTSM) software platform. Bioclinica AGILE RTSM provides seamless clinical ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... and collaboration, announces Mirroring360 Pro . This new addition to the Mirroring360 ... experience for education and business. , Mirroring360 Pro enables educators, business professionals and ...
(Date:4/25/2017)... Amherst, NY (PRWEB) , ... April 25, 2017 , ... ... much stress at work can also decrease overall productivity and performance in the workplace. ... their employees. , During the last few weeks of April, Clearview Resolution Services will ...
(Date:4/25/2017)... ... April 25, 2017 , ... The doctors at Wall Centre Dental are ... dental fear and require sedation to receive dental care. The doctors offer three treatment ... from hygienic cleanings to oral surgery, at their dental office in Vancouver. Wall Centre ...
Breaking Medicine News(10 mins):